IP Library › Granted Patent US 12,577,522
Granted Patent B2
US 12,577,522 · App. 17/325,593 · Granted Mar 17, 2026

System and method for screening therapeutic agents

Inventors: Philip LeDuc (Wexford, PA); Li Wan (Pittsburgh, PA); Carola Neumann (Pittsburgh, PA); John Skoko (Pittsburgh, PA); Jun Yin (Pittsburgh, PA); Mei Zhang (Pittsburgh, PA)
Assignees: Carnegie Mellon University; University of Pittsburgh—Of the Commonwealth System of Higher Education
C12M41/46C12M21/08C12M23/12C12M25/14C12M45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,577,522
App. No.
17/325,593
Granted
Mar 17, 2026
Kind
B2
Abstract

A drug screening device is provided. A method of determining optimal drug concentrations and efficacy in a patient using the device are provided. A method of determining effective chemotherapeutic drugs and effective concentrations thereof using the device is provided. Also, a method of determining safety and efficacy of drugs using the device is provided.

Claims (22)

1 . A device comprising:

a containment structure comprising a base and one or more walls and configured to hold a hydrogel therein;

a biocompatible hydrogel contained within the containment structure, the biocompatible hydrogel defining a plurality of wells configured to retain a therapeutic agent, the plurality of wells formed in the hydrogel, and wherein the hydrogel is configured to allow for diffusion of the therapeutic agent thereby forming a concentration gradient of the therapeutic agent within the hydrogel; and

a live, solid tissue sample embedded in the hydrogel and spaced apart from the first well,

wherein the concentration gradient allows for determination of an effective dose of the therapeutic agent based on a determination of an effect of the therapeutic agent on the tissue sample.

2 . The device of claim 1 , wherein the tissue sample is a contiguous tissue sample comprising a first portion and a second portion, that is arranged within the hydrogel so that the first portion is a first distance from the plurality of wells, and the second portion is a second distance from the plurality of wells that is greater than the first distance from the plurality of wells.

3 . The device of claim 1 , comprising two or more tissue samples spaced at different distances from the plurality of wells.

4 . The device of claim 1 , wherein each of the plurality of wells is the second well is a larger distance from another well the first well than from the tissue sample any of the two or more tissue samples.

5 . The device of claim 1 , wherein the tissue sample is arranged between the plurality of wells.

6 . The device of claim 1 , wherein the hydrogel comprises at least three wells spaced around the tissue sample or samples.

7 . The device of claim 1 , wherein at least one of the plurality of wells is elongated.

8 . The device of claim 7 , wherein at least one of the plurality of wells is a slot or channel.

9 . The device of claim 1 , comprising a therapeutic agent in at least one of the plurality of wells.

10 . The device of claim 1 , configured as a cartridge for use in an automated system for incubating and/or analyzing the tissue sample.

11 . The device of claim 1 , wherein at least one of the plurality of wells comprises a channel embedded within the hydrogel having outlets extending to a surface of the hydrogel.

12 . The device of claim 1 , wherein the tissue sample is a biopsy obtained from a human or veterinary patient.

13 . The device of claim 1 , wherein the tissue sample is a sample of an abnormal tissue mass.

14 . The device of claim 1 , wherein the hydrogel comprises an extracellular matrix material.

15 . A device comprising:

a biocompatible hydrogel defining at least a first well configured to retain a therapeutic agent, the at least first well formed in the hydrogel, wherein the hydrogel is configured to allow for diffusion of the therapeutic agent thereby forming a concentration gradient of the therapeutic agent within the hydrogel; and

a live, solid tissue sample embedded in the hydrogel and spaced apart from the first well,

wherein the concentration gradient allows for determination of an effective dose of the therapeutic agent based on a determination of an effect of the therapeutic agent on the tissue sample.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2026
From: NEUMANN, CAROLA; ZHANG, MEI; SKOKO, JOHN; YIN, JUN
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 074793/0968 →
CONFIRMATORY LICENSE Recorded Dec 5, 2023
From: CARNEGIE-MELON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065775/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2022
From: LEDUC, PHILIP; WAN, LI
To: CARNEGIE MELLON UNIVERSITY
Reel/Frame 058757/0872 →
Continuity (2)
Provisional Application 63027397 · May 20, 2020
Related Publication 20210363477A1 · Nov 25, 2021
References Cited (54)
US 11235330B2 · Hansen · 2022 [cited by examiner]
US 20060014273A1 · Yasuda · 2006 [cited by examiner]
US 20090041825A1 · Kotov · 2009 [cited by examiner]
US 20190187129A1 · Skardal · 2019 [cited by examiner]
Abbott, “Biology's new dimension”, Nature, 2003, pp. 870-872, vol. 424. [cited by applicant]
Asghar et al., “Engineering cancer microenvironments for in vitro 3-D tumor models”, Mater Today (Kidlington), 2015, vol. 18:10, pp. 539-553. [cited by applicant]
Begley et al., “Raise standards for preclinical cancer research”, Nature, 2012, vol. 483, pp. 531-533. [cited by applicant]
Bhattacharjee et al., “The upcoming 3D-printing revolution in microfluidics”, Lab Chip, 2016, vol. 16, pp. 1720-1742. [cited by applicant]
Cappetta et al., “Doxorubicin targets multiple players: A new view of an old problem”. Pharmacological Research, 2018, vol. 127, pp. 4-14. [cited by applicant]
Chang et al., “Parallel Microfluidic Chemosensitivity Testing on Individual Slice Cultures”, Lap Chip, 2014, pp. 4540-4551. [cited by applicant]
Chou et al., “Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design”, Journal of the National… [cited by applicant]
Chou, “Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies”, Pharmacological Review, 2006, vol. 58:3, pp. 621-681. [cited by applicant]
Chou, “Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method”, Cancer Research, 2010, vol. 70:2, pp. 440-446. [cited by applicant]
Croce et al., “Autofluorescence spectroscopy and imaging: a tool for biomedical research and diagnosis”, European Journal of Histochemistry, 2014, vol. 58:2460, pp. 320-338. [cited by applicant]
Culbertson, et al. “Diffusion coefficient measurements in microfluidic devices”, Talanta, 2002, vol. 56, pp. 365-373. [cited by applicant]
Emadi et al., “Cyclophosphamide and cancer: golden anniversay”, Nature, 2009, vol. 6, pp. 638-647. [cited by applicant]
Esch et al., “Organs-on-chips at the frontiers of drug discovery”, Nature, 2015, vol. 14, pp. 248-260. [cited by applicant]
Fisher et al., “Increased Intensification and Total Dose of Cyclophosphamide in a Doxorubicin-Cyclophosphamide Regimen for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowe… [cited by applicant]
Ganz et al., “Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: Doxorubicin and Cyclphosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and … [cited by applicant]
Gelmon et al., “Phase I/II Trial of Biweekly Paclitaxel and Cisplatin in the Treatment of Metastatic Breast Cancer”, Journal of Clinical Oncology, 1996, vol. 14:4, pp. 1185-1191. [cited by applicant]
Hachey et al., “Applications of Tumor Chip Technology”, Lab Chip, 2018, vol. 18:19, pp. 2893-2912. [cited by applicant]
Hosseini et al., “Bio-inspired microstructures in collagen type I hydrogel”, Journal Biomed Mater Research Part A, 2015, vol. 103A, pp. 2193-2197. [cited by applicant]
Huh et al., “From 3D cell culture to organs-on-chips”, Trends in Cell Biology, 2011, vol. 21:12, pp. 745-754. [cited by applicant]
Huh et al., “Microengineered physiological biomiimicry: Organs-on-Chips”, Lab Chip, 2012, vol. 12, pp. 2156-2164. [cited by applicant]
Kashaninejad et al., “Organ-Tumor-on-a Chip for Chemosensitivity Assay: A Critical Review”, Micromachines, 2016, vol. 7:130, pp. 1-24. [cited by applicant]
Kirson et al., “Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)”, BMC Medical Physics, 2009. vol. 9, pp. 1-13. [cited by applicant]
Kolesky et al., “Three-dimensional bioprinting of thick vascularized tissues”, PNAS, 2016, vol. 13:12, pp. 3179-3184. [cited by applicant]
Kolesky et al., “3D Bioprinting of Vascularized, Heterogenous Cell-Laden Tissue Contsructs”, Advanced Materials, 2014, vol. 26, pp. 3124-3130. [cited by applicant]
Kumar et al., “Preclinical screening methods in cancer”, Indian J Pharmacol, 2016, vol. 48:5, pp. 481-486. [cited by applicant]
Lawson et al., “The Cleared Mammary Fat Pad Transplantation Assay for Mammary Epithelial Organogenesis”, Cold Spring Harb Protoc, 2015, vol. 12, pp. 1-8. [cited by applicant]
Lee et al., “Three-dimensional culture models of normal and malignant breast epithelial cells”, Nat Methods, 2007, vol. 4:4, pp. 359-365. [cited by applicant]
Loessner et al., “Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells”, Biomaterials, 2010, vol. 31, pp. 8494-8506. [cited by applicant]
Lori et al., “Doxorubicin and syclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study”, Vet Comp Oncol, 2010, vol. 8:3, pp. 188-195. [cited by applicant]
Ma et al., “Biomimetic tumor microenvironment on a microfluidic platform”, Biomicrofluidics, 2013. vol. 7, pp. 1-13. [cited by applicant]
Matthews et al., “Mathematical Methods of Physics (Appendix only)”, 2nd Edition, 1979, W.a. Benjamin, Lebanon , Indiana, USA. [cited by applicant]
Mehndiratta et al., “Diagnostic Techniques and Surgical Management of Brain Tumors, Chapter 2—Brain Tumour Imaging”, InTech, 2011, pp. 27-42. [cited by applicant]
Motlagh et al., “Fluorescence properties of several chemotherapy drugs: doxorubicin, paclitaxel and bleomycin”, Biomedical Optics Express, 2016, vol. 7:6, pp. 1-7. [cited by applicant]
Muller et al., “Precise measurement of diffusion by multi-color dual-focus fluorescence correlation spectroscopy”, EPL, 2008, vol. 83, pp. 46001-p1-46001-p5. [cited by applicant]
Murphy et al., “3D bioprinting of tissues and organs”, Nature Biotechnology, 2014, vol. 32:8, pp. 773-785. [cited by applicant]
Nakada et al., “Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response”, Int J Gynecol Cancer, 2004, vol. 15, pp. 445-452. [cited by applicant]
Nguyen et al., “Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro”, PNAS, 2013, vol. 110-17, pp. 6712-6717. [cited by applicant]
Pampaloni et al., “The third dimension bridge the gap between cell culture and live tissue”, Nature Review Molecular Cell Biology, 2007, vol. 8, pp. 839-845. [cited by applicant]
Reddy, “Dietary Fat and Colon Cancer: Animal Studies”, Lipids , 1992, vol. 27:10, pp. 807-813. [cited by applicant]
Rosati et al.. “A Phase II Study of Paclitacel/Cisplatin Combination in Patients With Metastic Breast Cancer Refractory to Anthracycline-Based Chemotherapy”, Tumori, 2000, vol. 86, pp. 207-210. [cited by applicant]
Skardal et al., “A Reductionist Metastasis-on-a-Chip Platform for In Vitro Tumor Progression Modeling and Drug Screening”, Biotechnol Beoeng., 2016, vol. 113:9, pp. 2020-2032. [cited by applicant]
Sohn et al.. “Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer”, Cancer Research and Treatment, 2003, vol. 35:3, pp. 267-273. [cited by applicant]
Sokol et al., “Growth of human breast tissues from patient cells in 3D hydrogel scaffolds”, Breast Cancer Research, 2016, vol. 18:19, pp. 1-13. [cited by applicant]
Sparano et al., “Phase II Trial of Biweekly Paclitaxel and Cisplatin in Advanced Breast Carcinoma: An Eastern Cooperative Oncology Group Study”, J. Clin Oncol., 1997, vol. 15, pp. 1880-1884. [cited by applicant]
Szot et al., “3D in vitro bioengineered tumors based on collagen I hydrogels”, Biomaterials, 2011, vol. 32:31, pp. 7905-7912. [cited by applicant]
Tibbit et al., “Hydrogels as Extracellular Matrix Mimics for 3D Cell Culture”, Biotechnology and Bioenginnering, 2009, vol. 103:4, pp. 655-663. [cited by applicant]
Wan et al., “Mimicking Embedded Vasculature Structure for 3D Cancer on a Chip Approaches through Micromilling”, Scientific Reports, 2017, vol. 7:16724, pp. 1-8. [cited by applicant]
Wan et al., “Tumor-on-a-chip for integrating a 3D tumor microenvironment:chemical and mechanical factors”, Lab Chip, 2020, vol. 20, pp. 873-888. [cited by applicant]
Yuanlong et al., “Characteristic Autofluorescence for Cancer Diagnosis and Its Origin”, Lasers in Surgery and Medicine, 1987. vol. 7, pp. 528-532. [cited by applicant]
Zhao et al., “Off-the-shelf microsponge arrays for facile and efficient construction of miniaturized 3D cellular microenvironments for versatile cell-based assays”, Lab Chip. 2013, vol. 13, pp. 2350-2358. [cited by applicant]